Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for ...

Neurizon Therapeutics (ASX: NUZ) has announced encouraging outcomes from an independent study assessing its neuroprotective ...

Mach 7 and Universal Biosensors have announced their CEOs will depart, while changes at the top are likely at other biotechs.

Watch the video to see the initiatives Neurizon is taking. This video was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing. The interviews and ...

Neurizon teams up with Tessara for further testing on its ... Read More The post StockTake: Neurizon’s potential cure for ...

Neurizon Therapeutics Ltd (ASX:NUZ) has yielded positive results from an independent study – conducted in collaboration with ...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Tylah Tully gives the ...

Neurizon Therapeutics plans to implement several initiatives to get the clinical hold lifted of its IND application for NUZ-001. The company has been in discussion with the US FDA since February ...

Neurizon Therapeutics has submitted a formal request to the US FDA for advice on pharmacokinetic studies needed to lift hold on its IND application for NUZ-001 Neurizon Therapeutics (ASX ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the ...